Source Facts: Financial Supervisory Service Electronic Disclosure System (DART) / 2024-09-30
Disclosure Type: Major Management Matters Related to Investment Decisions
💡 3-Second Summary
On September 30, 2024, Celltrion submitted a Phase 3 Clinical Trial Application (IND) for ‘CT-P13 SC (Remsima subcutaneous formulation)’ in pediatric Crohn’s disease patients to the South Korean Ministry of Food and Drug Safety (MFDS).
📊 1. [Key Disclosure Content & Major Financial Figures Summary]
- Investigational Drug Name: CT-P13 SC (Remsima subcutaneous formulation, Active ingredient: Infliximab)
- Target Disease (Indication): Moderately to severely active Crohn’s disease in pediatric patients (aged 6-17 years)
- Clinical Trial Phase & Design: Phase 3 Clinical Trial (Randomized, double-blind)
- Application Date & Regulatory Body:
- Submission Date: September 30, 2024
- Reviewing Authority: South Korean Ministry of Food and Drug Safety (MFDS)
- Global Clinical Trial Registration Number: EU CT number 2023-507098-17
- Trial Protocol & Scope:
- Sample Size: 243 patients
- Treatment Duration: 106 weeks
- Objective: To compare and evaluate the efficacy of low-dose and high-dose CT-P13 SC maintenance therapy administered every 2 weeks to achieve clinical remission and endoscopic response at Week 54.
- Future Plans & Background:
- CT-P13 SC has completed Phase 3 clinical trials for adult patients with ulcerative colitis and Crohn’s disease and has obtained marketing authorization in multiple countries, including the US and Europe.
- The goal of this pediatric Phase 3 trial is to expand clinical treatment opportunities to pediatric patient populations, in addition to the approved adult indications.
- Fact Confirmation Date: September 30, 2024 (The date the application was formally submitted to the MFDS)
📈 2. [Expert Perspective: What This Disclosure Means for Investors]
This regulatory filing indicates that Celltrion has formally initiated the domestic regulatory process to expand its market segment by submitting a Phase 3 Clinical Trial Application (CTA/IND) in South Korea for its subcutaneous infliximab formulation, CT-P13 SC, targeting pediatric Crohn’s disease.
From a development perspective, submitting the Phase 3 clinical trial protocol marks the official entry into the clinical evaluation stage required to expand the product’s approved indications. However, as highlighted in the corporate cautionary notice, the historical statistical probability of an investigational clinical candidate successfully progressing to final marketing authorization is approximately 10%. Furthermore, this filing does not disclose projected clinical trial expenditures or prospective domestic market revenue upon commercialization. Investors should view this filing strictly as an administrative milestone representing the submission of the protocol rather than a final regulatory approval or a guarantee of clinical success.
📝 Editor’s Comment (by K-STOCK Editor)
Applied Comment Style: Cautionary View
This informational disclosure registers the submission of Celltrion’s domestic Phase 3 clinical protocol for CT-P13 SC in pediatric Crohn’s disease to the MFDS on September 30. The primary development is the initiation of administrative filings to expand the therapeutic scope of the approved adult formulation to pediatric patients aged 6 to 17.
Investors must emphasize that this filing represents a “submission of an application” rather than an authorized trial protocol. Depending on regulatory feedback or supplementary inquiries from the MFDS, the trial’s design parameters or the physical initiation date may be adjusted or delayed. Additionally, if the clinical trials yield results that do not meet expectations or if supplementary requirements arise during the marketing authorization process, the commercialization timeline remains subject to adjustments or deferrals.
Consequently, the objective checkpoints for investors to monitor going forward are twofold: first, subsequent disclosures confirming the formal Clinical Trial Application (IND) approval for CT-P13 SC in pediatric Crohn’s disease by the MFDS; and second, the subsequent verification of the actual clinical progress status (transitioning to active enrollment) under the R&D pipeline sections of future periodic corporate reports. Tracking these administrative development stages remains the necessary pathway to verifying the development of this clinical asset.
📢 Disclaimer & Source Information
Source: This content has been structured and newly drafted based on official data submitted to the Financial Supervisory Service Electronic Disclosure System (DART).
Investment Risk Warning: This content is provided for informational and linguistic reference purposes only. Under no circumstances does it constitute financial advice or a recommendation to buy or sell specific stocks. All investment decisions and financial liabilities rest solely with the investor.
Inquiries: For compliance inquiries or copyright-related requests, please contact ksb220805@gmail.com.
